Development of a novel AhR-based Cancer Treatment
ACT aims to establish preclinical efficacy and safety for a novel drug targeting advanced triple negative breast cancer (TNBC) via modulation of the aryl hydrocarbon receptor (AhR). The AhR is activated by aromatic hydrocarbons present in pollutants and is highly expressed in TNBC and other tumours. AhR activation has been linked to tumour initiation and metastasis, which can be significantly inhibited by AhR modulators. Our candidate compounds thus represent highly promising anti-cancer drugs.
3 527 860.00€
Pharmaceutical Products / Drugs